After a phase 3 push the livmoniplimab plan falters.
ApexOnco Front Page
Recent articles
The company discontinues one of its two KRAS G12D degraders.
IBI3020 beats Chengdu Kanghong's KH815 into clinical trials.
The company deprioritises its lead project, naporafenib, shifting to two Joyo-originated assets.
The group’s point-of-care Car-T push looks to have stalled.
GSK and iTeos dump belrestotug, with the latter now looking at “strategic alternatives”.
After earlier masked probody setbacks, CytomX surprises with CX-2051.
The conjugates SYS6005 and TQB2101 feature among first-in-human study entrants.
